Oncology Institute (TOIIW) Non-Current Deferred Tax Liability (2020 - 2025)

Oncology Institute has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $7.8 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 24171.88% year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2025 stood at $7.8 million (up 24171.88% YoY), and the FY2025 full-year result was $7.8 million, up 24171.88% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $7.8 million, up from $32000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $10.2 million in Q4 2023, with the low at $32000.0 in Q1 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $1.9 million across 5 years, with a median of $158000.0 in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability plunged 99.69% — and 2025, when it surged 24171.88%.
• Oncology Institute's Non-Current Deferred Tax Liability stood at $371000.0 in 2021, then surged by 2244.47% to $8.7 million in 2022, then climbed by 17.38% to $10.2 million in 2023, then sank by 99.69% to $32000.0 in 2024, then surged by 24171.88% to $7.8 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $7.8 million (Q4 2025), $32000.0 (Q1 2025), and $32000.0 (Q4 2024), per Business Quant data.